Antipodes Partners’s Amedisys AMED Stock Holding History

Antipodes Partners’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-77	Closed	-$6K	–	70
2022 Q4	$6K	Buy	+77	New	+$6.94K	﹤0.01%	68

Other funds holding AMED

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Antipodes Partners's AMED Position: Q1 2023 in Review

Antipodes Partners sold out of Amedisys (AMED) in Q1 2023, closing a stake of 77 shares — an estimated $6K sold.

Antipodes Partners first reported a position in AMED in Q4 2022 and held it in 1 quarter. The position peaked at $6K in Q4 2022. 281 funds tracked by Wall St. Rank hold AMED as of Q1 2023.

Antipodes Partners reported no remaining Amedisys position as of Q1 2023 after selling out during the quarter.
Antipodes Partners sold 77 Amedisys shares in Q1 2023, an estimated $6K.
Antipodes Partners first reported a position in Amedisys in Q4 2022 and held it in 1 quarter.
Antipodes Partners's Amedisys position peaked at $6K in Q4 2022.
281 funds tracked by Wall St. Rank held Amedisys as of Q1 2023.

Based on Antipodes Partners's 13F filing for Q1 2023, filed 11 May 2023.